Seppro depletion products enable scientists to measure more precisely the expression of protein biomarkers from a range of mammalian and plant biological samples. This acquisition covers current inventory, production technology and all future rights to produce and distribute the product lines.
The Seppro IgY depletion platform is an antibody-based technology for processing plasma, serum and plant samples. It enables researchers to detect and analyze commonly obscured biomarkers in samples by removing highly abundant proteins. Seppro depletion products are built using chicken-derived IgY antibodies, providing higher selectivity and lower cross-reactivity than other comparable products, the two companies said.
The library of 700 polyclonal IgY antibodies acquired from GenWay represents Sigma-Aldrich’s first IgY antibody offering. The new antibodies are derived from chicken embryos and prepared using recombinant antigens. With the acquisition of the chicken-derived IgY antibodies library, Sigma-Aldrich also plans to expand its antibody catalog, to which more than 8,000 new antibodies were added in 2008.
Dave Smoller, president of research biotech business unit at Sigma-Aldrich, said: The acquisition of Seppro significantly strengthens Sigma-Aldrich’s position in antibody-based depletion technology. Our goal, through acquisitions and collaborations, is to provide researchers with the most comprehensive and highly characterized portfolio of antibodies and antibody products.